Atlas Trials

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Clinical trial NCT05888493 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05888493
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Follicular Lymphoma (FL)
Start date
2023-10-02
Primary completion
2028-07-25
Enrollment
109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.